Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

109 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Inhaled Fluticasone Furoate for Outpatient Treatment of Covid-19.
Boulware DR, Lindsell CJ, Stewart TG, Hernandez AF, Collins S, McCarthy MW, Jayaweera D, Gentile N, Castro M, Sulkowski M, McTigue K, Felker GM, Ginde AA, Dunsmore SE, Adam SJ, DeLong A, Hanna G, Remaly A, Thicklin F, Wilder R, Wilson S, Shenkman E, Naggie S; ACTIV-6 Study Group and Investigators. Boulware DR, et al. Among authors: mccarthy mw. N Engl J Med. 2023 Sep 21;389(12):1085-1095. doi: 10.1056/NEJMoa2209421. N Engl J Med. 2023. PMID: 37733308 Free PMC article. Clinical Trial.
Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
Naggie S, Boulware DR, Lindsell CJ, Stewart TG, Gentile N, Collins S, McCarthy MW, Jayaweera D, Castro M, Sulkowski M, McTigue K, Thicklin F, Felker GM, Ginde AA, Bramante CT, Slandzicki AJ, Gabriel A, Shah NS, Lenert LA, Dunsmore SE, Adam SJ, DeLong A, Hanna G, Remaly A, Wilder R, Wilson S, Shenkman E, Hernandez AF; Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV-6) Study Group and Investigators. Naggie S, et al. Among authors: mccarthy mw. JAMA. 2022 Oct 25;328(16):1595-1603. doi: 10.1001/jama.2022.18590. JAMA. 2022. PMID: 36269852 Free PMC article. Clinical Trial.
Infliximab Concentrations in Participants with Moderate to Severe COVID-19.
Balevic SJ, Dandachi D, Dixon D, Hoetelmans RMW, Bozzette S, McCarthy MW; ACTIV‐1 Study Team. Balevic SJ, et al. Among authors: mccarthy mw. J Clin Pharmacol. 2024 Apr;64(4):490-491. doi: 10.1002/jcph.2388. Epub 2023 Dec 14. J Clin Pharmacol. 2024. PMID: 38031826 No abstract available.
Progress toward realizing the promise of decentralized clinical trials.
McCarthy MW, Lindsell CJ, Rajasingham R, Stewart TG, Boulware DR, Naggie S. McCarthy MW, et al. J Clin Transl Sci. 2024 Jan 14;8(1):e19. doi: 10.1017/cts.2023.706. eCollection 2024. J Clin Transl Sci. 2024. PMID: 38384913 Free PMC article. No abstract available.
Simnotrelvir as a potential treatment for COVID-19.
McCarthy MW. McCarthy MW. Expert Opin Pharmacother. 2024 Feb;25(3):233-237. doi: 10.1080/14656566.2024.2323597. Epub 2024 Feb 27. Expert Opin Pharmacother. 2024. PMID: 38393345 Review.
Treatment of severe COVID-19: an evolving paradigm.
McCarthy MW. McCarthy MW. Expert Opin Pharmacother. 2022 Dec;23(17):1887-1891. doi: 10.1080/14656566.2022.2140041. Epub 2022 Oct 28. Expert Opin Pharmacother. 2022. PMID: 36271630
Infliximab as a potential treatment for COVID-19.
Velez MP, McCarthy MW. Velez MP, et al. Among authors: mccarthy mw. Expert Rev Anti Infect Ther. 2023 Jan;21(1):1-5. doi: 10.1080/14787210.2023.2151438. Epub 2022 Nov 27. Expert Rev Anti Infect Ther. 2023. PMID: 36413380 Clinical Trial.
Montelukast as a potential treatment for COVID-19.
McCarthy MW. McCarthy MW. Expert Opin Pharmacother. 2023 Apr;24(5):551-555. doi: 10.1080/14656566.2023.2192866. Epub 2023 Mar 19. Expert Opin Pharmacother. 2023. PMID: 36927284 Review.
109 results